Phase 4 N=150 Breastfeeding Etonogestrel Implant Study
Contraception
Primary: Number of Participants With Continuation of Breastfeeding at 8 Weeks Postpartum — 54; 45; 48; 43 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=90 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants
Group B Streptococcal Infections
Primary: Safety and Tolerability of the GBS-NN/NN2 Vaccine for 4 Weeks After Each Dose of Vaccine — 23; 21; 5; 10 Participants
Phase 4 N=46 Sugammadex as Rescue Therapy
Neuromuscular Blockade
Primary: The Time Taken to Achieve a TOF Ratio of 0.9 After Administration Sugammadex — 3.13; 2.56; 2.33; 5.00 minutes
N/A N=1,472 Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Participants With Second Primary Malignancies (SPM) — 24 Participants
N/A N=130 A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
Peripheral Arterial Disease · Critical Limb Ischemia
Primary: Primary Efficacy Endpoint: Percentage of Participants With Technical Success of the Bare Temporary Spur Stent — 99.2 percentage of participants
Phase 2 N=189 A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Huntington's Disease
Primary: Change From Baseline in the SDMT — 2.0; 0.8 score on a scale — p=0.1675
Phase 1 N=53 RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
Covid19
Primary: Total Protein Normal to Abnormal Transition — 4.5; 4.6 percentage of participants — p=1.000
N/A N=135 Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) Trial
Type 1 Diabetes
Primary: Change in Hemoglobin A1c (HbA1c) Over Time — -0.34; -0.53; -0.34; -0.51 percentage of glycated hemoglobin — p=0.8875
N/A N=723 Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Thromboembolic Disease Recurrent · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Validation of the Wells DVT Clinical Decision Rule — 67; 186; 148; 4 Participants
Phase 2 N=300 Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
Healthy
Primary: Carcinogen Detoxification of Metabolites in Urine. — 7.26; 6.11; 3052.39; 1843.29 ng/mL
N/A N=584 The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)
Coronary Artery Disease
Primary: Number of Participants With Negative Invasive Coronary Angiography — 137; 24 Participants
Early Phase 1 N=27 Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
Primary Ciliary Dyskinesia
Primary: Baseline MCC (Ave60Clr; Average Clearance Over 60 Minutes) — 1.4; -1.1; 7.3 percent clearance — p=0.002
N/A N=1,424 Transfusion Trigger After Operations in High Cardiac Risk Patients
Myocardial Infarction · Coronary Revascularization · Acute Renal Failure
Primary: A Composite Endpoint of All-cause Post-randomization Mortality, Myocardial Infarction (MI), Coronary Revascularization, Acute Renal Failure, or Post-randomization…
N/A N=10 Auditory-Perceptual Training Via Telepractice
Speech Sound Disorder
Primary: Averaged Perception Percent Accuracy Score — 84.74 percent accuracy
Phase 2 N=14 A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
Parkinson's Disease
Primary: Incidence of Adverse Events Related to the Treatment — 0; 1; 0 Participants